Interim Data Support Elafibranor in Rare Chronic Liver Disease

(MedPage Today) — WASHINGTON — Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), according to interim results…